CO-ARROW-ELECTRONICS
9.6.2021 16:02:07 CEST | Business Wire | Press release
Global technology solutions provider Arrow Electronics (NYSE:ARW) and ROOQ, an innovator in sports measurement and analytics technology, have teamed up to create the ROOQ BOX, a sensor technology that enables boxers to monitor and review their performance using data that was previously only available under laboratory conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005194/en/
ROOQ BOX comprises a pair of sensors worn within a strap on each wrist. The sensors record the movements made during boxing activity. The data is then analyzed in the accompanying ROOQ app and cloud using machine learning algorithms to provide a precise record of the session. Using this information, boxers and trainers can create a detailed picture of the training session including punch count, punch speeds, variability and punch force. The algorithm has been trained to identify eight different types of punches and to automatically categorize these while filtering out non-boxing specific motions.
The data delivered by the sensor technology, which was inaccessible to athletes until now, provides an invaluable tool to help boxers monitor and improve their performance. This information can be shared with their coaches. In developing the system, ROOQ has drawn on a wide range of experience from within its team including data, software, hardware and firmware specialists, sports scientists and mathematicians as well as boxers and coaches. This experience reaches to the highest level: ROOQ’s chief sports officer, Henry Maske, is an Olympic boxing champion (gold medal, Seoul 1988) and professional world champion (1993 to 1996).
Arrow has been instrumental in leading the project in the firmware and hardware area between the suppliers of components, development and manufacturing services. Also, Arrow’s eInfochips engineering services were utilized in the project. Arrow has used its logistical and supply chain expertise to enable the product to be brought to market, and production scaled, in a smooth and efficient manner.
"This successful collaboration with ROOQ is a perfect example of how expert teams join forces and overcome difficult entrepreneurial challenges together," said Martin Bielesch, president of Arrow’s components business in EMEA. "Arrow's technical and logistical services enabled ROOQ to focus and execute on its leading competencies in delivering a completely new way of capturing diagnostic data in boxing."
Henry Maske sees many advantages in the cooperation between the two companies. "Arrow is a reliable and solution-oriented partner for us. We benefit from their immense experience as well as from their excellent global network.”
Boxing is just the beginning. The training diagnostics technology is universally applicable. Ralf Rüttgers, founder and CEO at ROOQ, is convinced that the application areas of ROOQ are manifold. He said, "Further development and transfer to the fitness market and other related sports, as well as use in the industrial sector, are all possible. Areas such as prevention, safety and health, will play a role in our future training analysis.”
About Arrow Electronics
Arrow Electronics guides innovation forward for over 180,000 leading technology manufacturers and service providers. With 2020 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com .
About ROOQ
ROOQ is about to enter the global market with its training analysis technology. The company employs an interdisciplinary team of over 25 people at its headquarters in Aachen, Germany. The technology model founded in 2018, is a novelty for boxing. For the first time, athletes and coaches receive individualized information on their training performance. For more information, visit rooq.de.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom